Wednesday, 24 April, 2024
HomeHepatologyBlood test predicts best therapy in HCV

Blood test predicts best therapy in HCV

A simple blood test can be used to predict which chronic hepatitis C (HCV) patients will respond to interferon-based therapy, research has found. "While highly effective direct-acting antivirals have become the new standard of care for patients with hepatitis C, these treatments come with a hefty price tag," said lead study author Dr Philipp Solbach, from Hannover Medical School, Niedersachsen, Germany. "There may still be a role for the more affordable interferon-based therapies, and with this new information, we can better assess which patients will respond to this less-expensive treatment."

The researchers studied a cohort of HCV-infected patients who received interferon-based therapies and found that levels of oxidised low-density lipoprotein (LDL) in the blood predicted the patient's response to treatment. LDL, commonly known as "bad cholesterol," is easily identified through blood testing, and can be used as a surrogate marker for oxidised LDL.

Once oxidised LDL was established as a marker of treatment response, the authors studied hepatitis C transmission from cell to cell using an in vitro culture system. They found that oxidised LDL inhibited cell-to-cell spread, suggesting a mechanism underlying the relationship between oxidised LDL and a sustained viral response to interferon therapy.

"The study provides important information about the mechanism whereby HCV infection occurs," added Dr Rebecca G Wells, associate editor of Cellular and Molecular Gastroenterology and Hepatology. "While direct-acting antivirals are coming to the forefront in HCV therapy, this study serves an important role in advancing our understanding of this complex virus."

This work raises the possibility that drugs that inhibit viral entry into cells may be useful add-ons to interferon therapy for hepatitis C virus; additionally, similar approaches may be effective for other chronic viral infections. Further studies testing entry-inhibiting drugs are needed.

[link url="http://www.eurekalert.org/pub_releases/2015-05/aga-nbm051315.php"]American Gastroenterological Association material[/link]
[link url="http://www.cmghjournal.org/article/S2352-345X(15)00058-2/fulltext"]Cellular and Molecular Gastroenterology and Hepatology abstract[/link]

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.